Aqueous processing of atosiban acetate for preterm labour management begins with the API dissolved in Water for Injections at a concentration equivalent to 7.5 mg/mL atosiban free base, using the acetate salt corrected for peptide content and water content. The formulation vessel is a jacketed stainless steel unit with bottom-mounted magnetic stirring; dissolution is completed at controlled temperature not exceeding 25°C to limit deamidation and oxidation. pH adjustment with dilute hydrochloric acid or sodium hydroxide targets a range between 4.0 and 5.0 because outside this window aqueous solubility and chemical stability of the nonapeptide deteriorate; osmolality is adjusted with sodium chloride or mannitol to 280–320 mOsm/kg. The bulk solution is passed through a 0.45 μm prefilter and two serial 0.22 μm sterilising-grade polyvinylidene fluoride or polyethersulfone filters under aseptic conditions; terminal moist-heat sterilisation at 121°C is avoided because the peptide is not thermally stable under saturated steam cycles. The filtered solution is filled into Type I borosilicate glass vials conforming to Ph. Eur. 3.2.1, closed with chlorobutyl rubber stoppers and aluminium flip-off seals. Terminal unit sizes are 0.9 mL containing 6.75 mg atosiban and 5 mL containing 37.5 mg, both clear colourless concentrates for intravenous use. Release testing includes sterility by Ph. Eur. 2.6.1, bacterial endotoxins by Ph. Eur. 2.6.14, sub-visible particulates by USP <787>, visible particulates by USP <790>, and release against marketing authorisation specifications under FDA 21 CFR 211.165. The finished product is diluted in 0.9% w/v sodium chloride or Ringer’s lactate to the 0.75 mg/mL infusion concentration used in clinical protocols.

What Limits Sterilising-Grade Filtration of Atosiban Acetate Solutions?

Sterilising-grade filtration of the 7.5 mg/mL concentrate presents two process risks that are not observed with small-molecule parenterals: membrane adsorption and shear-induced aggregation. Adsorption is controlled by selecting low-protein-binding membranes, typically hydroxyl-modified polyethersulfone or polyvinylidene fluoride with a nominal pore size of 0.22 μm; unmodified nylon and cellulose acetate membranes are avoided because peptide binding can reduce yield by more than 5% in early filtration scale-up trials. Differential pressure across the sterilising cartridge is maintained below the membrane manufacturer’s maximum, commonly 1.0–1.5 bar, and a 0.45 μm prefilter is installed to reduce plugging by peptide aggregates or silicone particles introduced from elastomeric components. Filter integrity is verified by bubble point or diffusive flow test in accordance with ASTM F838-20 before and after use to detect defects caused by pressure spikes during transfer. The filtered solution is held in a sterile stainless-steel or single-use disposable bag before filling; hold time is limited by in-process bioburden and peptide degradation data, typically supported by ICH Q1A-aligned stability studies. Batch records document pre-filtration bioburden, filter lot, integrity test values, and maximum differential pressure; the terminal product is a sterile, endotoxin-controlled concentrate without terminal heat sterilisation.

Lyophilised Atosiban Acetate for Unit-Dose Reconstitution

Lyophilisation is used when aqueous chemical degradation must be suppressed during storage or when the injection must be supplied as a dry powder for reconstitution in regions where cold-chain integrity is interrupted. Excipient screening for atosiban acetate lyophilisation typically evaluates mannitol or trehalose as cryoprotectants and bulking agents, with cryoprotectant-to-peptide mass ratios from 20:1 to 50:1 being common in peptide formulation development; published data specific to atosiban acetate collapse temperature and freeze-drying cycle parameters is limited, and cycle development therefore relies on freeze-drying microscopy and modulated differential scanning calorimetry rather than generic lyophilisation recipes. The process involves freezing the aqueous solution below the formulation collapse temperature, primary drying under vacuum with controlled shelf temperature ramping, and secondary drying to residual moisture below 2.0% w/w determined by Karl Fischer titration according to Ph. Eur. 2.5.12. Poor cake structure is a known failure mode when mannitol crystallises incompletely during annealing; annealing steps are therefore introduced above the mannitol crystallisation event when mannitol is the selected bulking agent. The terminal product is a white to off-white lyophilised cake in a Type I glass vial, closed under vacuum or nitrogen, and reconstituted with Water for Injections to 7.5 mg/mL atosiban before dilution for intravenous infusion. Container closure integrity after stoppering is verified by dye ingress or helium leak testing; moisture and related substances are monitored through shelf life under ICH Q1A conditions.

In oral solid dosage development, atosiban acetate faces gastric acid denaturation, luminal degradation by pepsin, trypsin, chymotrypsin, and brush-border peptidases, and poor permeability across the intestinal epithelium. The API is not currently marketed as an oral tablet or capsule, and published data for the oral bioavailability of atosiban acetate in humans is limited; formulation work therefore proceeds through enteric-coated systems combined with permeation enhancers and protease inhibitors. A typical trial tablet contains atosiban acetate at 1–5% w/w in a directly compressible matrix of microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate, compressed on a rotary tablet press with pre-compression and main compression forces in the range of 8–15 kN. The core is film-coated with an anionic methacrylic acid copolymer dispersion, such as a 30% w/w aqueous dispersion applied to a weight gain of 15–25% w/w, to prevent dissolution in simulated gastric fluid; disintegration then occurs above pH 5.5 in simulated intestinal fluid. Capsule configurations replace the tablet core with hard gelatin capsules containing peptide-loaded granules or a lyophilised peptide–mannitol premix, followed by the same enteric coating on the capsule shell or on pellets filled into the capsule. Dissolution is evaluated according to USP <711> and Ph. Eur. 2.9.3 using two-stage media; residual solvent and elemental impurity testing follows ICH Q3C and ICH Q3D. Since no pharmacopoeial monograph for oral atosiban acetate exists, specifications are derived from general peptide solid-dose acceptance criteria, and verification of activity must include receptor-binding assays because chemical purity alone does not confirm native conformation after manufacturing.

When Infusion Hardware Selects for Polyolefin Contact Layers Over Flexible PVC

Compatibility of the prepared infusion with administration sets and infusion bottles is assessed because atosiban acetate is diluted to 0.75 mg/mL and may remain in contact with plastic surfaces for up to 48 h. Flexible polyvinyl chloride sets plasticised with di(2-ethylhexyl) phthalate are not preferred for peptide infusions because the lipophilic plasticiser can migrate into the aqueous phase, and peptide adsorption to unmodified PVC has been reported for other nonapeptides. Polyolefin or polyethylene-lined administration sets are evaluated as lower-binding alternatives; extractable and leachable testing follows USP <661.1> and USP <1661>, with leachables assessed at the maximum in-use dilution and shelf-life temperature exposure. The infusion solution is prepared in 0.9% w/v sodium chloride or Ringer’s lactate; the diluted solution is visually inspected for precipitation and sub-visible particles at 0 h, 24 h, and 48 h using USP <787> methodology. Some infusion sets include small-bore connectors that must meet ISO 80369-7 to prevent misconnection; this is not specific to the API but is part of the finished in-use assembly because the concentrate is administered via infusion pump. The terminal product is a diluted, single-use infusion in a polyolefin container or glass bottle, prepared aseptically at the point of care and used within the stability window established by the marketing authorisation holder.

Multiparticulate Enteric-Coated Granules and Capsule Filling

Granulation of atosiban acetate is constrained by the low dose and the peptide’s sensitivity to moisture and shear, so low-shear wet granulation or fluid-bed spray granulation is used rather than high-shear granulation. In a top-spray fluid bed, the peptide is first dissolved or dispersed in an aqueous binder solution containing mannitol and low-viscosity hydroxypropyl methylcellulose, then sprayed onto microcrystalline cellulose starter pellets at product temperature 28–32°C and inlet air temperature 40–50°C; the granulate is dried to loss-on-drying below 2.0% w/w. Enteric coating of the granules uses an aqueous methacrylic acid-ethyl acrylate copolymer dispersion, often with triethyl citrate as plasticiser and talc as anti-tacking agent, applied to 15–30% w/w coating weight gain in a fluid-bed coater with bottom-spray Wurster insert. The coated granules are filled into hard gelatin capsules or sealed sachets; each unit is designed to deliver a low peptide dose, but no marketed oral granule product for atosiban acetate exists and published data on this specific configuration is limited. Critical process controls include granule size distribution, coating thickness uniformity, residual moisture, and acid-resistance testing in 0.1 N hydrochloric acid for 2 h followed by dissolution in pH 6.8 phosphate buffer according to Ph. Eur. 2.9.3. Terminal finished product is an enteric-coated multiparticulate granule filled into a capsule or sachet, intended to release atosiban acetate in the upper small intestine, but requiring protease inhibitor and permeation enhancer optimisation before therapeutic relevance can be claimed.